Chloroquine for Glioblastoma.

Phase 1

• Conditions: Glioblastoma
• Interventions: Drug: Placebo; Drug: Oral tablet

• Registration Number: NCT04772846
• Lead Sponsor: Egyptian Medical Syndicate

Brief Summary

Adjuvant chloroquine to the conventional treatment for glioblastoma; A randomized, single-blind, placebo-controlled, phase I/II trial.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-03-01
• Primary Completion: 2020-12-01
• Status Verified: 2021-02
• Study First Submitted: 2021-02-24
• Study First Submitted QC: 2021-02-25
• Last Update Submitted: 2021-02-25
• Study First Posted: 2021-02-26
• Last Update Posted: 2021-02-26
• Study Completion: 2021-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Histologically confirmed glioblastoma Adequate hematologic, hepatic, and renal function Karnofsky performance status score ≥ 70% Life expectancy ≥ six weeks

Exclusion Criteria

Abnormal severe un-controlled medical conditions

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo drug group	Placebo	-
Chloroquine group	Oral tablet	-

Primary Outcome Measures

Name	Time	Method
Survival duration after surgery	Three years

Secondary Outcome Measures

Name	Time	Method
End-point evaluation, survival at three years	Three years

Trial Locations

Locations (1)

Private clinics; 🇪🇬 Cairo, Egypt